biostudies-literatureUnknown16(17)Tissera S<h4>Introduction</h4>Lung cancer accounts for 9% of all cancer diagnoses in Australia with a 5-year survival rate of 26%. Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer, representing 15% of all lung cancer cases and a 5-year survival of 11.1%. This study aims to assess the extent of guideline concordant treatment (GCT) delivery for SCLC in Victoria, identify patient, clinical, and hospital factors influencing GCT receipt, and evaluate its impact on survival.<h4>Methods</h4>Data were obtained from the Victorian Lung Cancer Registry (VLCR) in Victoria, Australia (n = 1769). Descriptive statistics were used to summarie patient and disease characteristics by treatment type, including GCT, non-GCT, and no/declined treatment. Statistical analyses included multiple logiThoracic cancere70161https://www.ebi.ac.uk/biostudies/studies/S-EPMC12425560biostudies-literatureImpact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia.PMC12425560Olesen ITorres JZalcberg JTissera SJohn THarden SConron MRichardson GAntippa PCaldecott MParente PUnderhill CBillah BKarim MNWright GFaisal WStirling RGBlum RSamuel EParakh SSee KfalseImpact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia.<h4>Introduction</h4>Lung cancer accounts for 9% of all cancer diagnoses in Australia with a 5-year survival rate of 26%. Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer, representing 15% of all lung cancer cases and a 5-year survival of 11.1%. This study aims to assess the extent of guideline concordant treatment (GCT) delivery for SCLC in Victoria, identify patient, clinical, and hospital factors influencing GCT receipt, and evaluate its impact on survival.<h4>Methods</h4>Data were obtained from the Victorian Lung Cancer Registry (VLCR) in Victoria, Australia (n = 1769). Descriptive statistics were used to summarie patient and disease characteristics by treatment type, including GCT, non-GCT, and no/declined treatment. Statistical analyses included multiple logi2025-01-01T00:00:00Z2025 Sep2026-06-01T23:29:32.854Z2026-05-23T03:08:12.38ZS-EPMC124255604093536410.1111/1759-7714.70161